Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
PR90858
AMERSHAM, United Kingdom, July 27, 2021 /PRNewswire=KYODO JBN/ --
-- Major investments are expanding manufacturing capacity for life sciences
products at 13 Cytiva and Pall Corporation sites helping to meet customer
demand.
-- New sites opening in US and UK to realize regional manufacturing models.
Overall, the companies plan to hire 2000 full-time associates over the next two
years.
-- Investment follows five strategic acquisitions made by the companies this
year and is in addition to Cytiva's continuing capacity investments estimated
at 500 million USD through 2022.
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the
Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and
services across geographies (
) for global life sciences customers.
The investment, already underway, includes new sites, expansion at existing
factories, and is additional to previously announced investments. It follows
five acquisitions made by the companies so far this year.
Emmanuel Ligner, Danaher Group Executive, says: "Our customers tell us they
need access to manufacturing agility, a robust global supply chain and more
regional options. This investment further fuels our expansion program so we can
rapidly meet the current and future needs of our customers and ultimately,
their patients."
Cytiva and Pall Corporation's capacity expansion will increase the manufacture
of key products used to make biologic medicines.
The companies are investing:
-- 600+ million USD in chromatography resins – media for analyzing or
purifying biomolecules – establishing a new manufacturing site in the US.
-- 400+ million USD in cell culture media – in liquid or powder form this is
used to grow and cultivate cells before they are purified– expand
operations in the US, UK, and Austria.
-- 300+ million USD in single-use technologies – including bioreactor bags
for growing cells used to make personalized medicines and syringe filters
for scientific research – expand operations in the US and the UK, as well
as fitting out a new facility in Cardiff, Wales.
-- 200+ million USD for continuing expansion work in Cytiva and Pall
Corporation's sites across China and the rest of the Asia-Pacific region,
Europe, and the US.
This investment also addresses some of the key challenges highlighted in the
Global Biopharma Resilience Index (
), conducted by Longitude, a Financial Times company, and published by Cytiva
in March 2021. These include hiring and training talent, R&D collaboration,
supply chain resilience, manufacturing models, as well as government policy and
regulation.
About Pall
Pall Corporation is a filtration, separation and purification leader providing
solutions to meet the critical fluid management needs of customers across the
broad spectrum of life sciences and industry. Part of the Danaher (NYSE: DHR)
family of science and technology innovators, Pall works with customers to
advance health, safety and environmentally responsible technologies. The
Company's engineered products enable process and product innovation and
minimize emissions and waste. Pall Corporation serves customers worldwide. For
more information visit www.pall.com.
About Cytiva
Cytiva is a global life sciences leader with more than 8,000 associates across
40 countries dedicated to advancing and accelerating therapeutics. Part of the
Danaher (NYSE: DHR) family of science and technology innovators, Cytiva is a
trusted partner to customers that range in scale and scope, Cytiva brings
speed, efficiency and capacity to research and manufacturing workflows,
enabling the development, manufacture and delivery of transformative medicines
to patients. For more information visit www.cytiva.com.
SOURCE: Cytiva
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
